Melmet Tablets (Metformin)

• Composition :
  Each tablet contains Metformin 500 mg.
• Indications :
  As an adjunct to diet and exercise to improve glycemic control in adult patients with Type II Diabetes.
• Pharmacodynamics :
  Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
• Dosage and administration :
  The usual starting dose of Melmet Tablets is 500 mg twice a day given with meals. In general, clinically significant responses are not seen at doses below 1500 mg per day. Dosage increases should be made in increments of 500 mg weekly, up to a total of 2000 mg per day, given in divided doses.
• Contraindications :
  Renal impairment. Metabolic acidosis, including diabetic ketoacidosis. Hypersensitivity to metformin hydrochloride.
• Precautions and warnings :
  Lactic acidosis: Warn against excessive alcohol intake. Melmet is not recommended in hepatic impairment and is contraindicated in renal impairment. Ensure normal renal function before initiating and at least annually thereafter. Temporarily discontinue in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually. Macrovascular outcomes: No conclusive evidence of macrovascular risk reduction with Melmet or any other antidiabetic drug
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category B. Safety and effectiveness studies have not been conducted in nursing mothers. Paediatric Use: Safety and effectiveness in children younger than 18 years of age have not been established.
• Drug interactions :
  Cationic drugs: May reduce metformin elimination. Use with caution in patients who are taking cationic medications eliminated by renal tubular secretion.
• Adverse reactions :
  The most common adverse reactions reported are abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing and palpitation.
• Therapy Area :
  Anti-Diabetic agents